HRT Side Effects: What the Latest Research Shows About Risks and Benefits

Most HRT side effects, including breast tenderness, bloating, headaches and irregular bleeding, are mild and usually settle within one to three months. The serious risks of blood clots, stroke and breast cancer depend mainly on the estrogen route, the type of progestogen and when therapy starts: according to Manson et al. in JAMA (2013), women who began hormone therapy in their 50s or within 10 years of menopause had a more favorable balance of benefits and risks than the older women who dominated the original Women’s Health Initiative results.

Hormone replacement therapy has had an unusually turbulent evidence history. A single large trial published in 2002, the Women’s Health Initiative (WHI), caused millions of women to stop HRT within months, many of them abruptly, and the ripple effects on prescribing patterns lasted over two decades. The problem is that the WHI findings were substantially misinterpreted and overgeneralized, and the subsequent reanalyses tell a materially different story.

HRT is also called menopausal hormone therapy (MHT) or hormone therapy (HT), and it covers estrogen therapy alone (ET) and combined estrogen-progestogen therapy (EPT). Its side effect profile is not a single list. It changes with the estrogen route (oral, transdermal or vaginal), the progestogen used to protect the uterus, the dose, and a woman's age and time since menopause. The sections that follow take each risk in turn, then set out how to weigh them for an individual woman.

Common Side Effects by Delivery Method

Most common side effects of HRT are dose-dependent, delivery-method dependent, and typically resolve within one to three months as the body adjusts. The table below summarizes the pattern.

Side Effect	Oral Estrogen	Transdermal Estrogen (patch/gel/spray)	Vaginal Estrogen	Oral Progesterone/Progestogen	Progesterone IUD
Breast tenderness	Common (20-30%)	Less common (10-15%)	Rare	Common	Uncommon
Bloating/fluid retention	Common	Less common	Rare	Moderate	Uncommon
Headache/migraine	More common; variable estrogen levels	Less common; more stable levels	Rare	Less common with micronized progesterone	Uncommon
Mood changes/irritability	Uncommon	Uncommon	Rare	More common with synthetic progestogens (MPA); less with micronized progesterone	Variable
Nausea	Common (first 4-6 weeks)	Uncommon	Rare	Uncommon	Rare
Skin irritation	N/A	Uncommon (5-10%); rotate application sites	Rare	N/A	N/A
Irregular bleeding	Common in first 3-6 months	Common in first 3-6 months	Rare	More common with continuous combined	Common initially; then amenorrhea

These are side effects, not serious risks. They affect quality of life and are often why women discontinue HRT prematurely, but they can usually be managed with dose adjustment, formulation change, or delivery method switch. Switching from a synthetic progestogen (medroxyprogesterone acetate, norethisterone) to micronized progesterone (body-identical) often reduces mood and bloating-related side effects.

How long do HRT side effects last?

Breast tenderness, nausea, bloating and headaches usually ease within the first one to three months as estrogen levels stabilize. Irregular bleeding or spotting is common for the first three to six months, especially on a continuous combined regimen. Bleeding that persists beyond six months, starts after a bleed-free spell, or appears after menopause needs investigation rather than reassurance, because postmenopausal bleeding can signal endometrial changes.

Does HRT cause weight gain?

Standard-dose HRT has not been shown to cause weight gain in randomized trials. Midlife weight gain and a shift of fat toward the abdomen are driven by age, falling estrogen, sleep disruption and lower activity, and they happen with or without hormone therapy. Early fluid retention and bloating can feel like weight gain and usually settle within weeks. The wider picture of menopause weight gain has its own causes and fixes.

What the WHI Actually Showed, and Where It Went Wrong

The WHI enrolled women with a mean age of 63 years, most of whom were 10 or more years past menopause. Roughly 35% had metabolic syndrome. The HRT used was oral conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA), a synthetic progestogen not used in most contemporary HRT prescribing. The trial was halted in 2002 when interim analysis showed increased risks of coronary heart disease, stroke, blood clots, and breast cancer.

The 2013 reanalysis of WHI data, published in JAMA by Manson et al. (n=27,347), stratified results by age and time since menopause onset. Women who initiated HRT in their 50s, or within 10 years of menopause, showed a more favorable pattern: lower rates of coronary events and all-cause mortality in some analyses, fewer hip fractures, and a smaller burden of harm than older women. The harms seen in the original analysis were concentrated in older late-initiator women, the majority of the WHI population, not in women using HRT at typical menopause-treatment ages.

The 18-year follow-up by Manson et al. (JAMA, 2017) found that neither CEE alone nor CEE plus MPA increased all-cause, cardiovascular or cancer mortality over the long term. The original 2002 publication applied the findings from 63-year-old women, many with existing cardiovascular disease, to 50-year-old women just entering menopause. These are not the same population, and the risk-benefit calculation is not the same.

Why Did the FDA Change the HRT Warning Label?

The FDA requested removal of the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning on menopausal hormone therapy in November 2025. According to the FDA's labeling notice of 10 November 2025, the boxed warning about endometrial cancer stays on systemic estrogen-alone products, and labels now recommend starting systemic HRT within 10 years of menopause onset or before age 60.

The first six products received the updated labeling in February 2026, according to the FDA announcement of 12 February 2026. The risks themselves did not disappear: the information moved out of the box and into the body of the label. The change reflects the same evidence summarized here, that age, timing, route and progestogen type determine the risk, rather than a single warning for every woman.

Blood Clot Risk: Oral vs Transdermal Estrogen

This is one of the most clinically significant distinctions in HRT prescribing. Oral estrogen undergoes first-pass liver metabolism, which increases hepatic production of clotting factors and raises venous thromboembolism (VTE) risk by approximately two-fold compared to non-use. This is a real and consistent finding across multiple studies.

Transdermal estrogen, delivered through patches, gels, or sprays, bypasses hepatic first-pass metabolism. A landmark 2003 case-control study by Scarabin et al. in The Lancet found that oral, but not transdermal, estrogen was associated with higher VTE risk. The larger ESTHER study by Canonico et al. (Circulation, 2007) (n=271 cases, 610 controls) found a four-fold higher VTE risk with oral estrogen (odds ratio 4.2) and no elevation with transdermal estradiol (odds ratio 0.9), and micronized progesterone was not associated with added risk.

A 2008 meta-analysis in BMJ by Canonico et al. confirmed this finding across 17 studies, with an odds ratio of 2.5 for oral estrogen and 1.2 (not statistically significant) for transdermal estrogen. Women with personal or family history of VTE, obesity, prolonged immobility, or thrombophilia (such as Factor V Leiden) should be prescribed transdermal rather than oral estrogen. For women without these risk factors, both routes are considered acceptable, and the transdermal route removes most of the added VTE risk seen with oral estrogen.

Stroke Risk

Oral estrogen is associated with a modest increase in ischemic stroke risk (approximately 30% relative increase over baseline) based on WHI and observational data. The absolute risk increase is small in younger women with low baseline stroke risk, but it is not zero.

Transdermal estradiol at standard doses does not appear to increase stroke risk. A 2010 nested case-control study in BMJ by Renoux et al. (n=15,710 women with stroke, 59,958 controls) found that current use of low-dose estradiol patches was not associated with elevated stroke risk, while high-dose patches and oral estrogen at any dose were associated with an increase. This is another reason to prefer transdermal delivery, particularly in women with migraine with aura (which itself elevates stroke risk).

Breast Cancer: Parsing the Nuance

Breast cancer risk is the primary concern most women and clinicians cite regarding HRT. The evidence is more nuanced than headlines suggest.

Estrogen-Only HRT

In the WHI estrogen-only arm (women who had undergone hysterectomy, using CEE alone, n=10,739), women in the HRT group had a lower incidence of breast cancer than the placebo group after 7 years of follow-up. The hazard ratio was 0.77, meaning a 23% lower relative risk of breast cancer in the HRT group. This finding is often omitted from summaries of WHI risks. Estrogen-only HRT in appropriate candidates (women without a uterus) did not increase breast cancer risk over 7 years in this trial and may reduce it, although large observational studies report a small increase with long-term use.

Combined Estrogen-Progestogen HRT

The combined arm (CEE plus MPA) showed a modest increase in breast cancer risk that emerged after five years of continuous use, with a hazard ratio of approximately 1.24 (24% relative risk increase). In absolute terms, this translated to roughly 8 additional breast cancer cases per 10,000 women per year of use.

Critically, the type of progestogen matters. A large 2020 study by Vinogradova et al. in BMJ (n=98,611 breast cancer cases) found that the added risk with combined HRT varied by progestogen, highest with norethisterone and lowest with dydrogesterone. The clearest data on micronized progesterone come from the French E3N cohort of 80,377 women, where Fournier et al. (2008) reported a relative risk of 1.00 for estrogen plus progesterone, compared with 1.69 for estrogen plus other synthetic progestins. This is consistent with laboratory evidence that micronized progesterone does not stimulate breast cell proliferation in the way that synthetic progestogens do.

The absolute risk numbers help calibrate the clinical conversation. Breast cancer occurs in approximately 23 women per 1,000 over 5 years in the 50-59 age group without HRT. With combined HRT using synthetic progestogens for 5 years, this rises to approximately 28 per 1,000. With estrogen plus micronized progesterone, the excess risk appears to be smaller and may approach that of estrogen-only in some analyses. Obesity alone confers a comparable or larger breast cancer risk increase than combined HRT in this age group, a comparison the British Menopause Society uses in its patient materials.

Does the risk last after stopping HRT?

Breast cancer risk rises with duration of use and falls after stopping, but not instantly. The worldwide meta-analysis by the Collaborative Group on Hormonal Factors in Breast Cancer (The Lancet, 2019) found that the excess was larger for combined than for estrogen-only therapy, that some excess persisted for more than a decade after longer use, and that vaginal estrogen showed little or no excess. The data are observational, so they show association rather than cause.

Cardiovascular Benefit: The Timing Window

The healthy artery hypothesis, supported by the ELITE trial, holds that estrogen’s cardiovascular benefits (reduced atherosclerosis progression, improved endothelial function, favorable lipid changes) are only realized when therapy is initiated before significant arterial disease has developed. Starting estrogen in women with established atherosclerotic plaques can destabilize plaques and raise early coronary event risk, which is what the WHI observed in its older population.

The ELITE trial (n=643), published by Hodis et al. in the New England Journal of Medicine (2016), found that women who initiated oral estradiol within 6 years of menopause showed significantly less carotid intima-media thickness progression (a marker of atherosclerosis) over 5 years than placebo, while women who started 10 or more years after menopause showed no such difference. The KEEPS trial in recently menopausal women found no harm to the arteries but no significant difference in intima-media thickness. Carotid thickness is a surrogate marker, so the structural benefit suggests, rather than confirms, lower long-term cardiovascular disease risk.

Current consensus from the British Menopause Society, the Menopause Society (formerly NAMS), and the European Menopause and Andropause Society is that HRT initiated in women under 60, or within 10 years of menopause, has a favorable cardiovascular risk-benefit profile and should not be withheld on cardiovascular grounds in otherwise appropriate candidates. The 2022 hormone therapy position statement of the Menopause Society sets out the same timing principle.

Does HRT Increase Dementia Risk?

Dementia risk from HRT depends on age at starting. The WHI Memory Study by Shumaker et al. (JAMA, 2003) found roughly double the rate of probable dementia (hazard ratio 2.05) in women aged 65 and older who started CEE plus MPA, which is why the probable dementia warning entered the label. That population was older than most women who start HRT today.

In recently menopausal women, the KEEPS cognitive substudy (Gleason et al., PLOS Medicine, 2015) found no cognitive harm and no cognitive benefit over four years. Some Danish registry data have linked HRT use to dementia diagnoses, but those studies cannot separate the hormone from the reasons women were prescribed it. The FDA began removing the probable dementia warning from HRT labels in November 2025. Midlife memory lapses and menopause brain fog are common and are not a sign of dementia.

Gallbladder Disease

Oral estrogen increases biliary cholesterol saturation and gallbladder bile stasis, raising the risk of gallstone formation. The WHI found approximately a 40% increase in gallbladder disease (mainly gallstones requiring surgery) in the oral HRT group. Transdermal estrogen has not been consistently associated with elevated gallbladder risk, as the hepatic first-pass effect is avoided. This is another reason to prefer transdermal delivery in women with existing gallbladder disease or risk factors.

Endometrial Protection: Why Progesterone Matters

Unopposed estrogen, meaning estrogen given without progesterone, significantly increases endometrial cancer risk in women with an intact uterus. The relative risk with unopposed oral estrogen use for 10 years approaches 10-fold over baseline. This was established well before the WHI and is not contested, and it is the one boxed warning the FDA kept on systemic estrogen-alone products.

Adequate progestogen or progesterone must be given to any woman with an intact uterus receiving systemic estrogen. The minimum dose and duration required to achieve full endometrial protection depends on the specific agent. For micronized progesterone 200 mg taken for 12-14 days per month (sequential regimen) or 100 mg daily (continuous regimen), endometrial protection is well-established. The levonorgestrel-releasing intrauterine system (LNG-IUS, a hormonal IUD) provides local endometrial protection with minimal systemic absorption and is used in some women who want to avoid systemic progestogen side effects.

Vaginal Estrogen: Side Effects and Safety

Low-dose vaginal estrogen has a different risk profile from systemic HRT because very little reaches the bloodstream. It is used for genitourinary syndrome of menopause (GSM), which includes atrophic vaginitis, vaginal dryness, painful sex and recurrent urinary tract infections. It comes as estradiol tablets, creams, rings and inserts, and low-dose vaginal DHEA (prasterone) is an alternative.

Side effects are mostly local: mild burning or irritation, discharge, and occasional spotting, which should still be reported. According to the Menopause Society, low-dose vaginal estrogen does not usually require an added progestogen, and the Lancet meta-analysis described above found little or no excess breast cancer risk with vaginal use. Breast cancer survivors considering vaginal estrogen should decide with their oncologist.

Bioidentical and Compounded Hormones: Are the Side Effects Different?

Bioidentical hormones have the same molecular structure as the hormones the ovaries make, and FDA-approved versions already exist: estradiol patches, gels, sprays and tablets, and oral micronized progesterone. Their side effects and risks are the ones described throughout this page, because they are the products most of the newer studies examined.

Compounded bioidentical hormone therapy (cBHT), made to order by compounding pharmacies as creams, troches or pellets, is not FDA approved and is not tested for consistent dosing. A 2020 report from the National Academies of Sciences, Engineering, and Medicine concluded that there is insufficient evidence to support the clinical utility of compounded products over approved ones. Hormone pellets cannot be removed once placed and can produce high, prolonged hormone levels. Compounded regimens are usually cash pay. The guide to bioidentical hormone therapy covers the differences in more depth.

Who Should Avoid HRT

Absolute contraindications to systemic HRT include: active or recent breast cancer (estrogen receptor-positive), active or recent endometrial cancer, unexplained vaginal bleeding, active venous thromboembolism (though transdermal estrogen may be considered once anticoagulated), and active liver disease with impaired liver function.

Relative contraindications requiring careful individualized assessment include: history of hormone-sensitive cancer, personal history of VTE (transdermal estrogen substantially mitigates risk), thrombophilias, migraine with aura (avoid oral estrogen; transdermal may be appropriate), severe active cardiovascular disease, and liver disease with normal liver function. Personal history of breast cancer is the most common contraindication encountered; management in breast cancer survivors involves oncologist input and depends on cancer type and stage.

Monitoring Schedule

Women starting HRT should be reviewed at 3 months to assess symptom response, side effect profile, and any early concerns. Annual review thereafter covers: continued symptom control and dose appropriateness, blood pressure (oral estrogen can raise it modestly in susceptible women), breast screening per age-appropriate national guidelines (not more frequent than standard for most HRT users), and a reassessment of the ongoing benefit-risk balance.

There is no universal stopping age for HRT. Current guidance from most specialist societies is that HRT should be continued as long as the individual woman continues to benefit from it, with annual re-evaluation of risks. The practice of stopping HRT at 60 or after a fixed 5-year period is not evidence-based and is increasingly being abandoned in specialist practice.

Weighing Your Personal Risk

The decision to use HRT is individual. Key inputs are: severity of menopausal symptoms (hot flashes, sleep, mood, cognitive, sexual), age and time since menopause, personal cardiovascular risk profile, personal and family history of breast cancer, thrombotic history, bone density, and personal preference regarding treatment approach and monitoring commitment.

For most women in their late 40s and 50s who are within 10 years of menopause onset and have no contraindications, the benefit-risk balance clearly favors HRT when symptoms significantly affect quality of life. The strongest risk mitigation strategy is to use transdermal estradiol combined with body-identical micronized progesterone, which substantially reduces the VTE, stroke, gallbladder, and breast cancer concerns associated with older formulations.

The table below sets the serious risks for the two systemic estrogen routes side by side, using the studies cited in the sections above.

For a complete guide to hormone replacement therapy including dosing, formulation selection, and monitoring protocols, see the hormone replacement therapy guide.

Who Prescribes HRT and How to Find a Clinic

HRT is prescribed by gynecologists (OB-GYNs), primary care physicians, family nurse practitioners, endocrinologists and clinicians who hold the Menopause Society Certified Practitioner (MSCP) credential. Breast cancer survivors and women with a past blood clot usually need their oncologist or hematologist involved as well. A menopause specialist is worth seeking when side effects persist after one or two formulation changes.

The directory of hormone therapy clinics across the US lists practices that offer HRT, from conventional gynecology to integrative and cash-pay hormone clinics. Listing order is not paid ranking, Featured slots are labeled and capped, Verified means the clinic completed credential checks rather than paying for placement, and Regenerated.com is free for patients. Inclusion in the directory is not an endorsement, and how Featured, Verified and organic listings differ is set out in its own guide.

FDA-approved estradiol and micronized progesterone are often covered by insurance, while compounded hormones and pellets are usually paid out of pocket. Before a first visit, these questions help compare clinics:

1. Which estrogen route do you usually start with, and why for my history?
2. Which progestogen do you use for women with a uterus, and is it micronized progesterone?
3. Do you prescribe FDA-approved products, compounded hormones, or pellets?
4. When is the first review, and how do you handle bleeding or breast tenderness?
5. Who coordinates with my oncologist or cardiologist if I have a relevant history?

The HRT treatment guide explains the options in more detail, and the overview of menopause treatment approaches covers non-hormonal choices for women who should not take estrogen.

Frequently asked questions about HRT side effects

What are the most common side effects of HRT?

The most common side effects of HRT are breast tenderness, bloating, headaches, nausea, mood changes and irregular bleeding or spotting. Most are mild and settle within one to three months, while bleeding can take up to six months to settle. Transdermal estradiol tends to cause less nausea and fewer headaches than oral estrogen, and micronized progesterone tends to cause fewer mood and bloating problems than synthetic progestogens such as medroxyprogesterone acetate.

Is the HRT patch safer than the pill?

For blood clots, stroke and gallbladder disease, the patch has the better safety record. Oral estrogen roughly doubles venous thromboembolism risk, while transdermal estradiol was not associated with a significant increase in a 2008 BMJ meta-analysis by Canonico and colleagues. Low-dose patches were not linked to higher stroke risk in a 2010 UK study. Breast cancer risk depends mostly on the progestogen and duration, not on whether estrogen comes as a patch or a pill.

Does HRT cause breast cancer?

HRT slightly raises breast cancer risk when it combines estrogen with a synthetic progestogen for more than about five years. In the WHI, that meant roughly 8 extra cases per 10,000 women per year. Estrogen alone, used by women without a uterus, was linked to fewer breast cancers than placebo over about 7 years. Estrogen with micronized progesterone showed no increase in the French E3N cohort, and vaginal estrogen shows little or no excess risk.

Does HRT make you gain weight?

HRT does not cause meaningful weight gain in randomized trials. Weight gain around menopause is driven by age, falling estrogen, poor sleep and lower activity, and it happens with or without hormone therapy. Some women notice fluid retention or bloating in the first weeks, which usually settles. If bloating persists, switching from oral to transdermal estrogen or from a synthetic progestogen to micronized progesterone often helps.

How long can you stay on HRT?

There is no fixed time limit on HRT. The Menopause Society's 2022 position statement and other specialist bodies advise continuing for as long as benefits outweigh risks, with a review at least once a year. The older rule of stopping at 60 or after five years is not supported by current evidence. Women who started before 60 can often continue past that age when symptoms return off treatment and their risk profile allows it.

What happens when you stop HRT?

When HRT stops, menopausal symptoms such as hot flashes, night sweats and poor sleep return for many women, often within weeks. Tapering the dose and stopping abruptly have not clearly differed in long-term symptom return in trials, so the choice is usually personal. Protection against bone loss fades after stopping. Breast cancer risk from combined HRT falls after stopping but can persist at a lower level for years after long use.

---

Related Reading

• Hormone Replacement Therapy (HRT): Types, Evidence, Risks, Who It Helps, and What to Ask Your Doctor
• Migraine: Types, Root Causes, Regenerative Treatments, and What Actually Helps